Results from Phase II MASH trial announced at EASL 2024

Boehringer Ingelheim's survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and ...

Gannex Announces Poster Presentation of Positive Interim 12-Week ...

... Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024 ... Ascletis Announces Promising ...

Zealand Pharma announces that Boehringer Ingelheim will present ...

... results from Phase 2 trial with survodutide in MASH at EASL. Company announcement - No. 29 / 2024. Zealand Pharma announces that Boehringer ...

Breakthroughs in MASH: Highlights from EASL 2024

The EASL 2024 ... Breakthroughs in MASH: Highlights from EASL 2024 ... Survodutide shows promising results in phase II trials for MASH and liver ...

survodutide top-line results MASH fibrosis - Boehringer Ingelheim

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant ...

Lilly's tirzepatide was superior to placebo for MASH resolution, and ...

INDIANAPOLIS , June 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, ...

Gannex to Present Positive Interim 12-Week Results from ASC41 ...

The Phase II clinical trial for ASC41, conducted in China, is a randomized, double-blind, placebo-controlled, multi-center study. The trial aims ...

Zealand Pharma announces that Boehringer Ingelheim will

... results from Phase 2 trial with survodutide in MASH at EASL. Copenhagen, Denmark, June 6, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) today ...

Akero Therapeutics Presents Poster and Late-breaking Oral ...

A third clinical trial, the SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4 fibrosis), is expected to be ...

Boehringer, Zealand's GLP-1 MASH Data 'Unintentionally ...

The new results show the trial met a secondary endpoint that looked at improvement of fibrosis without worsening of MASH, one of the efficacy ...

Survodutide Phase II trial shows 83% of adults treated

The trial met its primary endpoint with survodutide reaching a biopsy-proven improvement in MASH after 48 weeks, without worsening of fibrosis ...

Altimmune Showcases Pemvidutide Data at EASL 2024 for MASH ...

The trial showed that up to 75% of subjects at intermediate-to-high risk of MASH progression had their risk reduced to low after 24 weeks of ...

89bio to Present 48-Week Data from ENLIVEN Phase 2b ...

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International ...

Sagimet Biosciences Presents Data from ITT and F3 Patient ...

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International ...

Altimmune Presents Data at EASL International Liver Congress ...

... (MASH) at the EASL International Liver Congress™ 2024 in Milan, Italy . “These data, coupled with MOMENTUM Phase 2 obesity trial results that ...

Gilead to Present Latest Research Across Key Liver Disease ...

... (EASL) Congress, June 5-8, 2024 in ... Interim results for two years from the ASSURE study ... Final results of the Phase 2b MYR204 study ...

ABSTRACT BOOK | EASL Congress

Page 1. VOLUME 80 Suppl. 1 JUNE 2024 easlcongress.eu. #EASLCongress ... Phase II clinical studies of G-TAK, a novel and innovative therapeutic ... results from ...

Liver biopsy evaluation in MASH drug development: Think thrice, act ...

Primary endpoint(s) definition in ongoing phase III trial. MASH, metabolic dysfunction-associated steatohepatitis; NAFLD, non-alcoholic fatty liver disease; NAS ...

Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial ...

Data presented at the EASL Congress demonstrating 91% efficacy in halting or improving liver stiffness, a key noninvasive measure of fibrosis, at three years ...

Sagimet Biosciences Reports First Quarter 2024 Financial Results ...

We look forward to presenting the full FASCINATE-2 Phase 2b 52-week biopsy results at EASL in June 2024 . We plan to start a Phase 3 clinical ...